The story appears on

Page A11

June 21, 2018

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Finance

WuXi Biologics expands

WUXI Biologics, a Hong Kong-listed biopharmaceutical company, said yesterday that construction of a US$20 million integrated biologics conjugate R&D and manufacturing center has started in Wuxi in neighboring Jiangsu Province.

To be operational in 2019, the 6,000-square-meter facility will provide integrated solutions from concept to commercialization of biologics conjugates including Antibody-Drug Conjugates (ADCs) and other protein conjugates.

ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug, which has been adopted for a number of innovative treatments for targeted tumor therapy.

 




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend